Switch theme
Sign up to access all valuation multiples
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.
1998
5.4K+
LTM Revenue $4.0B
LTM EBITDA $1.4B
$9.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ipsen has a last 12-month revenue (LTM) of $4.0B and a last 12-month EBITDA of $1.4B.
In the most recent fiscal year, Ipsen achieved revenue of $4.0B and an EBITDA of $1.3B.
Ipsen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ipsen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.0B | XXX | $4.0B | XXX | XXX | XXX |
| Gross Profit | $3.3B | XXX | $3.3B | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 83% | XXX | XXX | XXX |
| EBITDA | $1.4B | XXX | $1.3B | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 33% | XXX | XXX | XXX |
| EBIT | $1.2B | XXX | $773M | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $551M | XXX | $389M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ipsen's stock price is EUR 102 (or $115).
Ipsen has current market cap of EUR 8.5B (or $9.5B), and EV of EUR 8.2B (or $9.2B).
See Ipsen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.2B | $9.5B | XXX | XXX | XXX | XXX | $11.56 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ipsen has market cap of $9.5B and EV of $9.2B.
Ipsen's trades at 2.3x EV/Revenue multiple, and 7.0x EV/EBITDA.
Equity research analysts estimate Ipsen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ipsen has a P/E ratio of 17.3x.
See valuation multiples for Ipsen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.5B | XXX | $9.5B | XXX | XXX | XXX |
| EV (current) | $9.2B | XXX | $9.2B | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 6.5x | XXX | 7.0x | XXX | XXX | XXX |
| EV/EBIT | 7.4x | XXX | 11.9x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 17.3x | XXX | 24.5x | XXX | XXX | XXX |
| EV/FCF | 13.5x | XXX | 61.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIpsen's last 12 month revenue growth is 7%
Ipsen's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.5M for the same period.
Ipsen's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ipsen's rule of X is 54% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ipsen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | 19% | XXX | XXX | XXX |
| Rule of 40 | 34% | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 54% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 63% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ipsen acquired XXX companies to date.
Last acquisition by Ipsen was XXXXXXXX, XXXXX XXXXX XXXXXX . Ipsen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ipsen founded? | Ipsen was founded in 1998. |
| Where is Ipsen headquartered? | Ipsen is headquartered in France. |
| How many employees does Ipsen have? | As of today, Ipsen has 5.4K+ employees. |
| Who is the CEO of Ipsen? | Ipsen's CEO is Mr. David Loew. |
| Is Ipsen publicy listed? | Yes, Ipsen is a public company listed on PAR. |
| What is the stock symbol of Ipsen? | Ipsen trades under IPN ticker. |
| When did Ipsen go public? | Ipsen went public in 2005. |
| Who are competitors of Ipsen? | Similar companies to Ipsen include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Ipsen? | Ipsen's current market cap is $9.5B |
| What is the current revenue of Ipsen? | Ipsen's last 12 months revenue is $4.0B. |
| What is the current revenue growth of Ipsen? | Ipsen revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Ipsen? | Current revenue multiple of Ipsen is 2.3x. |
| Is Ipsen profitable? | Yes, Ipsen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ipsen? | Ipsen's last 12 months EBITDA is $1.4B. |
| What is Ipsen's EBITDA margin? | Ipsen's last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Ipsen? | Current EBITDA multiple of Ipsen is 6.5x. |
| What is the current FCF of Ipsen? | Ipsen's last 12 months FCF is $685M. |
| What is Ipsen's FCF margin? | Ipsen's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Ipsen? | Current FCF multiple of Ipsen is 13.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
